Ca 19-9

Frequently Asked Questions (FAQs)

The quantitative measurement of CA 19-9 in serum is used as an aid in monitoring patients diagnosed with pancreatic cancer. Serum CA19-9 concentrations carry independent predictive value for the determination of resectability of pancreatic cancer and of overall patient survival. Elevated CA 19-9 concentrations discriminate between pancreatic cancer and benign pancreatic disease. Elevated concentrations are found in patients with pancreatic (80%) hepatobiliary (67%) gastric (40% to 50%) hepatocellular (30% to 50%) colorectal (30%) and breast (15%) cancer. Non-cancerous conditions that may elevate CA 19-9 antigen levels include cirrhosis, cholangitis, hepatitis, pancreatitis and non-malignant gastrointestinal diseases. This test should not be interpreted as absolute evidence for the presence or absence of malignant disease. The test value should be used in conjunction with findings from clinical evaluation and other diagnostic procedures. This test is not recommended for screening general population for pancreatic cancer.